| NArea Drugs and Therapeutics Committee Meeting Minutes<br>Wednesday 18th December 2024 10-12pm<br>Microsoft Teams Meeting | | |
|---|---|---|
| **Present:** | Mehrdad Malekian (Chair)<br>Victoria Gemmell (Prof Sec)<br>Tyra Smyth<br>Graeme Bryson<br>Colin Angus | Rachael Kelly<br>Kirsty Macfarlane<br>Stephanie Dundas<br>Penny Brankin<br>Christine Carswell |
| **1. Apologies:** | Craig Thurtell<br>Chris Miller | Alistair Brown |
| **2. Declaration of Interest** | **nil** | |

| Item | Notes | Action |
|---|---|---|
| **3.** | **<u>Minutes/Actions from the last meeting</u>**<br>These were agreed as a true reflection of the meeting and can be published. | RK |
| **4.** | **<u>Matters Arising</u>** | |
| **a)** | **Mirikizumab (Omvoh) Clinical Protocol - Conor Cronin - Update awaited** | |
| **b)** | **Refeeding Syndrome Guideline - Pamela Miller – Update**<br>Changes made as previously requested. Electrolyte monitoring reference now links to RDS website. It is acknowledged that previously requested calcium guidance is in progress, but publication of this guidance should not be delayed pending this.<br>Guideline was approved with no further changes, and may be published on RDS. | |
| **c)** | **Vabysmo Clinical Protocol – Tony Carson (Meena Virdi) - Update awaited** | |
| **d)** | **Acute Stroke – Thrombolysis and Thrombectomy Pathway - Mark Barber**<br>Some further changes were requested.<br>To return for final approval. | |
| **e)** | **Motor Neurone Disease - Linda Johnstone - Update awaited** | |
| **f)** | **Guidelines Submission Form**<br>This is an amalgamation of two forms. Feedback was received and discussed. Minor amendment will be made and submission form will be rolled out and audited. | |
| **g)** | **Director of Pharmacy – Update**<br>GB shared a presentation on a proposal for the evolution of medicines governance and ADTC. The plan includes creation of several subgroups which would feed into ADTC. There would be transparency and accountability throughout the process. The committee felt it would be helpful to have subgroups which include relevant experts to support clinical oversight. Inclusion of a Vice Chair would also be a welcome addition and help support succession planning. | |

| | | |
|---|---|---|
| **5.** | **SMC Advice-CONFIDENTIAL**<br><br>**Full Submissions**<br><br>• vamorolone (Agamree) Santhera Pharmaceuticals (Deutschland) GmbH SMC2721 **ACCEPTED with PAS-**treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older. **REFER TO NEUROLOGY FOR ADVICE**<br><br>• sirolimus (Hyftor) Plusultra pharma SMC2710 **ACCEPTED with PAS** for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older. **REFER TO DERMATOLOGY FOR ADVICE**<br>• relugolix / estradiol / norethisterone acetate (Ryeqo) Gedeon Richter (UK) Ltd SMC2666 **ACCEPTED** in adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. **REFER TO GYNAECOLOGY FOR ADVICE**<br>• danicopan (Voydeya) Alexion Pharmaceuticals SMC2675 **ACCEPTED RESTRICTED with PAS** as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia. **REFER TO HAEMATOLOGY FOR ADVICE**<br>• iptacopan (Fabhalta) Novartis Pharmaceuticals UK Limited SMC2676 **ACCEPTED RESTRICTED with PAS** As monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. **REFER TO HAEMATOLOGY FOR ADVICE**<br><br>**Abbreviated Submissions**<br><br>• closporin (Cequa) Sun Pharma UK Limited SMC2739 **ACCEPTED RESTRICTED:** treatment of moderate-to-severe Dry Eye Disease (keratoconjunctivitis sicca) in adult patients who have not responded adequately to artificial tears. **REFER TO OPHTHALMOLOGY FOR ADVICE**<br>• risankizumab (Skyrizi) AbbVie Ltd SMC2686 **ACCEPTED with PAS REFER TO GASTROENTEROLOGY FOR ADVCIE**<br>• ubilituximab (Briumvi) Neuraxpharm UK Ltd SMC2731 **ACCEPTED RESTRICTED with PAS** treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. **REFER TO NEUROLOGY FOR ADVICE**<br>• crovalimab (PiaSky) Roche Products Limited SMC728 **ACCEPTED RESTRICTED with PAS** as monotherapy for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH): **REFER TO HAEMATOLOGY FOR ADVICE**<br><br>**NON SUBMISSIONS**<br>• bictegravir / emtricitabine / tenofovir alafenamide (Biktarvy®) Gilead Sciences Ltd SMC2760 **FOR NOTING** A point was raised regarding potential current use of this within NHSL. This will be investigated further.<br>• rozanolixizumab (Rystiggo) UCB Pharma Limited SMC2761 as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. **FOR NOTING** | |

| | | |
|---|---|---|
| | **Ultra orphan medicine-DEFERRED ADVICE**<br>• fosdenopterin powder for solution for injection (Nulibry®) Sentynl Therapeutics Inc SMC2624 – for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A **REFER TO NEONATOLOGY FOR ADVICE**<br><br>**FOR INFORMATION**<br><br>SMC2492 atezolizumab (Tecentriq)<br>**Draft guidance for use of molnupiravir for treatment of COVID-19**<br>Draft guidance for public consultation has been published by the National Institute for Health and Care Excellence (NICE). The recommendations are draft and may change following public consultation. SMC has had direct input into the decision-making committee that produced the draft guidance. The final published advice will have the same status for health board consideration as other SMC advice on new medicines. The draft guidance is open for public consultation until **17 December 2024**. Anyone with an interest in this topic is encouraged to send their comments on the draft recommendation. Visit the NICE website to access the draft recommendation and to comment: Consultation \| Molnupiravir for treating COVID-19 [ID6340] \| Guidance \| NICE<br>**FOR NOTING**<br><br>**Paediatric Licence Extensions**<br>FOR INFORMATION | |
| **6.** | **SMC follow up**<br><br>RK outlined proposed designation updates from the follow-up, including ivosidenib, Kaftrio, Symkevi and Orkambi. RK made the committee aware of medicines which have passed their decision expected by date but which discussions around their use in NHS Lanarkshire are ongoing, including Tirzepatide, rimegepant, Symbicort Turbohaler and Hemgenix. | RK |
| **7.** | **Lanarkshire Formulary**<br>Formulary Amendment Form SyreniRing<br>Formulary Amendment Gygel Spermicide SBAR<br>Formulary Amendment Isotretinoin Acitretin SBAR<br>Proposed Formulary Amendments December 2024<br>Formulary Amendment Cinacalcet Tablets<br><br>These were accepted. | RK |
| **8.**<br><br>**(a)** | **Clinical Protocols**<br><br>**AMC Surgical Prophylaxis – Stephanie Dundas**<br>This was a significant piece of work to review existing guidance. These have been shared with the various surgical specialties and updated with relevant comments and suggestions. It was noted that there are limitations with current version of HEPMA which limits prescribing of surgical prophylaxis by theatres. There have been a significant number of errors and near misses in which HEPMA prescribing is a factor at the UHW site. This was also raised as an issue in Emergency Departments, especially when patients are transferred to a different site, or downstream wards. Contributing factors also include | |

| | | |
|---|---|---|
| | when activity is high and patients remain in ED rather than transfer to wards. This will be taken forward via hospital management teams, and the Medicines Safety Group at UHW. GB advised to add to site risk register, and will follow up with GR.<br>All guidelines approved and can be shared via the RDS website. | |
| **(b)** | **Paracetamol Guideline – Sarah Brady**<br>This is an update to the previous version, including additional information of salt content of soluble tablets. A comment was received regarding the use of paracetamol suppositories. It was agreed that reference to these may be helpful. This will be fed back to the author | |
| **(c)** | **SBAR – Changes to the Blood Monitoring Requirements - Conor Cronin**<br>This was discussed and the requested changes agreed. | |
| **(d)** | **Produodopa - Graham McCallum**<br>This was discussed. Previous concerns regarding pump delivery system have been resolved. There were several comments which will be fed back to the author.<br>The item will also need to be discussed at Acute PMB for cost and operational approval once it has been approved from a clinical perspective.<br>The document is not approved at this time, and should return for final approval once the above areas have been addressed. | |
| **(e)** | **Difelikefalin - Alison Yule**<br>This was discussed. It was approved on clinical grounds, however it will proceed through the usually processes for cost and operational approval. | |
| **(f)** | **Neonatal Monographs SBAR – Kirsty MacFarlane**<br>This was discussed and plans to move documents approved. | |
| **9.** | **ADTC New Medicines Decisions**<br>This was accepted. Update to medicine designations as per Follow-Up. | |
| **10.**<br>**(a)** | **Unlicensed Medicines**<br>**nil** | |
| **11.** | **Medication and Clinical risk in Lanarkshire**<br>https://www.gov.uk/drug-safety-update<br>It has been highlighted that there is a fault with the risk assessment calculator on the website www.assign-score.com. Clinicians were requested to STOP using the website immediately. RK liaised with CG team to ensure a statement has been added to the relevant NHSL guideline section to inform users. They will be directed to use either alternative calculators such as those available on GP prescribing systems, or NHSL guideline on management of cholesterol in adults | |
| **12.** | **Regional Cancer Advisory Network**<br>nil | |
| **13.** | **Patient Safety Alerts**<br>nil | |

| | | |
|---|---|---|
| **14.** | **<u>Lay member related items</u>**<br>nil | |
| **15.**<br>**(a)** | **<u>Correspondence</u>**<br>**<u>ADTC Collaborative</u>**<br>nil | |
| **16.** | **Pharmacy & NMAHP Prescribing Governance**<br>nil | |
| **17.**<br>**(a)**<br><br><br><br><br><br><br><br>**(b)** | **<u>AOCB</u>**<br>**PGD update Kirsty Macfarlane**<br>Meds guidance team took over PGD oversight recently and there are plans to present an updated to the current policy at January ADTC. There are also plans to create and maintain a database to manage and track these. It has been identified that there are 11 PGD's which have expired. These currently cannot be used in practice. This will be fed back to site chief nurses as a matter of urgency. The team will continue to try and locate authors and ensure these are updated as soon as possible. Plan for PGD amnesty, requesting for all and any PGD's to be shared to allow the Med Guidance Team to have full oversight.<br><br>**2025 proposed meeting dates**<br>These were agreed. | KMAC |
| **18.** | **<u>Date of next meeting</u>**<br><br>Wednesday 22nd January 2025 10-12pm<br>MS TEAMS | |